Show simple item record

dc.contributor.authorElias-Jones, A. C.
dc.contributor.authorDhillon, S.
dc.contributor.authorGreenough, A.
dc.date.accessioned2014-02-26T16:00:29Z
dc.date.available2014-02-26T16:00:29Z
dc.date.issued1985-10
dc.identifier.citationElias-Jones , A C , Dhillon , S & Greenough , A 1985 , ' The efficacy of oral theophylline in ventilated premature infants ' , Early Human Development , vol. 12 , no. 1 , pp. 9-14 .
dc.identifier.issn1872-6232
dc.identifier.otherPURE: 2097886
dc.identifier.otherPURE UUID: 5efa1359-925a-4f6b-9214-3491012e287e
dc.identifier.otherScopus: 0021962876
dc.identifier.urihttp://hdl.handle.net/2299/12924
dc.description.abstract40 ventilated premature infants, with gestational ages of 24-34 weeks and a mean birthweight of 1422 g, were entered into a randomised controlled trial. 20 of the infants received orally 5 mg/ml anhydrous theophylline dissolved in 20% pure alcohol, with a loading dose of 5 mg/kg and then 1.25 mg/kg every 6 h. Plasma samples were assayed via an emit enzyme immunoassay, demonstrating satisfactory serum levels in all infants at 54 h after the loading dose. Possible side-effects were seen only in two infants, in one a tachycardia (220 beats/min) and the other became agitated during treatmenten
dc.language.isoeng
dc.relation.ispartofEarly Human Development
dc.titleThe efficacy of oral theophylline in ventilated premature infantsen
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionCentre for Clinical Practice, Safe Medicines and Drug Misuse Research
dc.contributor.institutionPatient and Medicines Safety
dc.description.statusPeer reviewed
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record